Month: June 2021

The leading tour operator in the Baltic States “Novaturas” announced in February about signed EUR 10 million investment agreement in company’s’ bonds with the State Investment Management Agency for a period of six years. Almost a month ago, the leader of the tourism sector received the first part of the investment – EUR 5 million for ordinary bonds emission. On the 15th of June, “Novaturas” group received the second part of the investment for convertible bonds worth EUR 5 million. The company will allocate the first part of the investment received for ordinary bonds to its strategic priorities – development of relations with partners abroad, strengthening e company’s positions in the holiday destinations and improvement of the e-commerce system. “We were one of the first companies to have agreed on this kind of investment and...

Following the five-year strategy and developing one of the main therapeutic areas, JSC Olainfarm and Adalvo have signed a licensing and supply agreement to launch a new product in the urology segment which is targeted to be the 1st to market opportunity in all of these markets. The prescription product will help millions of patients in 17 different countries to regain ease and quality of life. In partnership Olainfarm will manage product regulatory affairs, distribution and promotion in Latvia, Russia, Kazakhstan, Belarus, Ukraine, and other countries of current presence and Adalvo will be responsible for development, manufacturing and will support Olainfarm for its market access activities in all the markets. Currently, Olainfarm has established a sustainable business model in the EU and CIS countries with more than 300 medical and marketing...

EfTEN Real Estate Fund III AS established a subsidiary EfTEN Ramygalos UAB, which acquired two industrial buildings in Panevezys, Lithuania. The buildings will be used by the electrical systems manufacturer AQ Wiring and UAB ADAX on the basis of lease agreements.  EfTEN Ramygalos UAB, a subsidiary of the Fund, entered into a purchase and sale agreement with UAB Adax and UAB BSP Industrial Property for the acquisition of three registered immovables in Panevežys, Lithuania, at Matininkų 9B, Ramygalos 190E and Ramygalos 194E, where two industrial buildings are located. The transaction price without VAT was 10 million euros, of which 4 million euros was equity and 6 million euros a loan taken from Šiaulių bank. The unleveraged initial yield of the investment properties is 8.0% annually. The transaction was completed on 15.06.2021. The financial...

Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKET™ MARSEILLE, France, June 16, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual investor event on Wednesday, June 23, 2021, at 2 p.m. CEST / 8 a.m. EDT. The event will feature presentations and an interactive Q&A session from the Company’s executive leadership team as well as Martine Bagot, M.D., Ph.D., Professor and Head of the Dermatology Department at the Saint-Louis Hospital, University of Paris, France. Pr. Bagot will present preliminary mycosis fungoides data from the Company’s Phase 2 TELLOMAK trial evaluating its lead product, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing...

Marseille, France, June 16, 2021 (GLOBE NEWSWIRE) — Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKETTMInnate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual investor event on Wednesday, June 23, 2021, at 2 p.m. CEST / 8 a.m. EDT. The event will feature presentations and an interactive Q&A session from the Company’s executive leadership team as well as Martine Bagot, M.D., Ph.D., Professor and Head of the Dermatology Department at the Saint-Louis Hospital, University of Paris, France. Pr. Bagot will present preliminary mycosis fungoides data from the Company’s Phase 2 TELLOMAK trial evaluating its lead product, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing...

Lochem, 16 June 2021           Adrie van der Ven to leave ForFarmers Adrie van der Ven will leave ForFarmers as of 1 January 2022. This has been decided in mutual understanding. Van der Ven will remain COO and member of the Executive Board until 1 October 2021 and will subsequently stay on as advisor until the end of the year. This will allow a smooth transition of his tasks and responsibilities in the coming period. Yoram Knoop, CEO of ForFarmers: “Adrie joined the Executive Board in 2019. He has made a significant contribution to the realisation of the strategy Build to Grow 2025, for which I am grateful to him. In addition, the important step to the growth market Poland was made under his leadership. On behalf of myself and my colleagues I want to wish him the best for the future.” The Executive Board, in consultation with the Supervisory...

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, June 15, 2021 (GLOBE NEWSWIRE) — Digihost Technology Inc. (“Digihost” or the “Company”) (TSXV: DGHI; OTCQB: HSSHF) is pleased to announce that the Company has entered into subscription agreements with certain institutional investors, for gross proceeds of approximately CAD$15 million in a private placement of its equity securities, comprised of 8,333,336 common shares of the Company (“Shares”) and warrants to purchase up to 6,250,002 common shares (“Warrants”), at a purchase price of CAD$1.80 per Share and associated Warrant. The Warrants have an exercise price of CAD$1.99 per Share and exercise period of three years from the issuance date. The net proceeds of the private placement will be used by the Company primarily to acquire...

SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 3,787,879 shares of its common stock at a price to the public of $33.00 per share. All of the shares of common stock are being offered by RAPT. Gross proceeds to RAPT from the offering are expected to be approximately $125 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 568,181...

MONACO, June 15, 2021 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced today that it has entered into separate, privately negotiated, agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2022 (the “Existing Notes”) to exchange approximately $19.4 million in aggregate principal amount of the Existing Notes for approximately $19.4 million in aggregate principal amount of new 3.00% Convertible Senior Notes due 2025 (the “Exchange Notes” and such transaction, the “Exchange Offer”). In addition, the Company has entered into separate, privately negotiated, agreements with certain investors to issue and sell approximately $42.4 in aggregate principal amount of the new 3.00% Convertible Senior Notes due 2025 (the “Purchased Notes”, and together with the...